Armata Pharmaceuticals
Armata Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics to combat antibiotic-resistant bacterial infections. Headquartered in Los Angeles, California, Armata leverages proprietary bacteriophage technology, synthetic biology, and in-house manufacturing to create high-impact therapeutics aimed at addressing the global challenge of antibiotic resistance. The company's mission is to develop and commercialize a pipeline of bacteriophage therapeutics while preserving the human microbiome, with a vision to become the global leader in phage-based treatments.
Industries
Nr. of Employees
medium (51-250)
Armata Pharmaceuticals
Marina Del Rey, California, United States, North America
Patents
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View Details
Bacteriophage for treatment and prevention of E. coli and B. fragilis infections
US-12268720-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-12239677-B2
View DetailsTherapeutic bacteriophage compositions for treating Staphylococcus infection
US-11654166-B2
View DetailsProducts
Clinical-stage bacteriophage therapeutic candidates targeting antibiotic-resistant infections
Pipeline of investigational, pathogen-specific bacteriophage therapeutic candidates being developed to treat difficult-to-treat and antibiotic-resistant bacterial infections.
AP-PA02
AP-PA02 is a therapeutic phage cocktail targeting the pathogen P. aeruginosa to treat serious respiratory infections, such as in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.
AP-PA03
A bacteriophage product candidate targeting Pseudomonas aeruginosa pneumonia.
AP-SA02
AP-SA02 is a fixed multi-phage product candidate that targets Staphylococcus aureus, offering potent antimicrobial activity against MSSA and MRSA strains, biofilm penetration, and synergistic benefits with standard of care antibiotics.
Synthetic Phage Platform
Armata's proprietary synthetic phage platform utilizes synthetic biology tools to engineer natural phages with improved pharmacological properties, expanded host range, improved potency, and biofilm disruption capabilities for treating multidrug-resistant bacterial infections.
Clinical-stage bacteriophage therapeutic candidates targeting antibiotic-resistant infections
Pipeline of investigational, pathogen-specific bacteriophage therapeutic candidates being developed to treat difficult-to-treat and antibiotic-resistant bacterial infections.
AP-PA02
AP-PA02 is a therapeutic phage cocktail targeting the pathogen P. aeruginosa to treat serious respiratory infections, such as in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis.
AP-PA03
A bacteriophage product candidate targeting Pseudomonas aeruginosa pneumonia.
AP-SA02
AP-SA02 is a fixed multi-phage product candidate that targets Staphylococcus aureus, offering potent antimicrobial activity against MSSA and MRSA strains, biofilm penetration, and synergistic benefits with standard of care antibiotics.
Synthetic Phage Platform
Armata's proprietary synthetic phage platform utilizes synthetic biology tools to engineer natural phages with improved pharmacological properties, expanded host range, improved potency, and biofilm disruption capabilities for treating multidrug-resistant bacterial infections.
Services
Integrated discovery, engineering, formulation, GMP manufacture, preclinical evaluation, and clinical development of pathogen-specific phage therapeutics.
Integrated discovery, engineering, formulation, GMP manufacture, preclinical evaluation, and clinical development of pathogen-specific phage therapeutics.
Expertise Areas
- Phage therapeutics development
- Clinical trial management for biologics
- cGMP manufacturing and manufacturing scale-up
- Quality management systems and release testing
Key Technologies
- Bacteriophage isolation and characterization
- Synthetic biology for phage engineering
- Phage/biologic formulation technologies
- cGMP manufacturing for investigational biologics
News & Updates
Armata's Fight Against Antibiotic Resistance
Armata is leading efforts to develop phage therapeutics to combat antibiotic-resistant bacteria.
Clinical Development of Phage Therapies
Progress in clinical trials for bacteriophage treatments for bacterial infections.
The Role of Phages in Modern Medicine
An overview of bacteriophage therapy and its potential to address antibiotic resistance.
Innovations in Bacteriophage Engineering
Advances in synthetic biology enabling tailored phage therapies.
Leading the Fight Against Antibiotic Resistance
Armata is recognized as a pioneer in bacteriophage therapeutics.
Regulatory Milestones in Phage Therapy
Achieved key regulatory approvals for clinical trials.
Armata's Fight Against Antibiotic Resistance
Armata is leading efforts to develop phage therapeutics to combat antibiotic-resistant bacteria.
Clinical Development of Phage Therapies
Progress in clinical trials for bacteriophage treatments for bacterial infections.
The Role of Phages in Modern Medicine
An overview of bacteriophage therapy and its potential to address antibiotic resistance.
Innovations in Bacteriophage Engineering
Advances in synthetic biology enabling tailored phage therapies.
Leading the Fight Against Antibiotic Resistance
Armata is recognized as a pioneer in bacteriophage therapeutics.
Regulatory Milestones in Phage Therapy
Achieved key regulatory approvals for clinical trials.